All articles by Vemula Pravalika
Vemula Pravalika
Mindray Showcased Latest Innovations in Smart Hospital Solutions at Arab Health 2024
Mindray (“the company”), a leading global provider of medical devices and solutions, is attending one of the largest exhibitions in the medical field, the Arab Health 2024 from Jan. 29 to Feb. 1. This year, under the theme of “Exploring the Future of Smart Healthcare”, Mindray showcased its latest innovations in Smart Hospital Solutions at its booth.
Fapon at Medlab Middle East 2024: Advancing Local Healthcare through IVD Technologies
Fapon, a global leading life sciences company, is showcasing its comprehensive one-stop IVD solutions and sharing the latest industry insights with global IVD professionals at Medlab Middle East 2024 in Dubai, UAE, from Feb 5 to Feb 8. Dedicated to leveraging its cutting-edge technologies and vast industry experience, Fapon aims to support the growth of the local IVD industry, enhancing local healthcare services while strengthening its global diagnostics ecosystem.
Beckman Coulter Diagnostics Appoints Kevin O’Reilly as New President
Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced Kevin O’Reilly’s appointment as its new president succeeding Julie Sawyer Montgomery, who is now vice president and group executive, Danaher Diagnostics.
Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer, Expanding Portfolio With Proven Six Sigma Performance
New analyzer complements hub labs by advancing capabilities of satellite and independent community hospital labs
Mindray Plans $927 Million Deal to Control APT Medical
On January 28th, Mindray announced its intention to acquire control of APT Medical (688617.SH), a medical device company listed on the Sci-Tech Innovation Board of Shanghai Stock Exchange, using its own funds of 6.65 billion yuan ($927 million) through a combination of “share transfer by agreement and waiver of voting rights.” This move aims to position Mindray in the cardiovascular field strategically.
QIAGEN Digital Insights launches ultra-fast NGS analysis for somatic cancer
QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, today announced their enhanced QIAGEN CLC Genomics Workbench Premium with LightSpeed technology now supports next-generation sequencing (NGS) for somatic cancer secondary analysis. The software accelerator converts raw sequencing data in FASTQ files to interpretable lists of genetic variants in VCF files at unprecedented low cost and high speed.
Effective wound-bed preparation
Correct wound bed preparation in chronic wounds accelerates healing and enhances the effectiveness of advanced wound care products. Katie Bennett – an NHS nurse with special interest in tissue viability, who runs a leg ulcer clinic, and treats complex and challenging wounds – explains why B Braun’s Prontosan Irrigation Solution, Wound Gel X and Debridement Pad provide the best foundation for wound healing.
Save time and lives with improved diagnostics
Q-linea develops and delivers solutions for the diagnosis of infectious diseases, with a keen focus on improving sepsis treatment while reducing antibiotic resistance. Christian Giske, professor and senior physician at the Department of Clinical Microbiology, Karolinska Institute, Sweden; Tiziana Di Martino, chief medical officer at Q-linea; and Jonas Jarvius, CEO at Q-linea, explain the benefits offered by the company’s range of diagnostic equipment.
Reduce antibiotic use with point-of-care testing
Growing antibiotic resistance is an increasing menace for healthcare authorities worldwide, compromising their efforts to battle infections in the clinical space. Afinion CRP from Abbott is a point-of-care test that can help avoid the misuse of antibiotics and in so doing, increase the number of positive outcomes for patients.
Enable early detection of congenital CMV infection
For over 40 years, DiaSorin Molecular has been developing, producing and commercialising diagnostic tests in a wide range of clinical areas including paediatrics, oncology, women’s health and infectious diseases. The company is about to launch its first Simplexa kit for the detection of congenital human cytomegalovirus (CMV), which poses significant dangers to newborns all across the globe.